Please assess the completion status of the following clinical trial:

Trial Title: Standard Chemotherapy vs. Chemotherapy Guided by Cancer Stem Cell Test in Recurrent Glioblastoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Men and Women and members of all ethnic groups who are at least 18 years old at the time of enrollment are eligible for this trial;~2. Informed consent obtained and signed;~3. Willing and able to commit to study procedures including long-term follow-up visit(s);~4. Histopathologically confirmed 2016-WHO grade III recurrent glioma, and grade IV recurrent glioblastoma (GBM), inclusive of Gliosarcoma~5. In all cases, the diagnosis must be confirmed by a pathologist.~6. Recurrent surgically resectable tumor and/or biopsy;~7. Participants who have undergone surgical resection should have received an MRI or a scan after surgery in order to visualize residual tumor. If not, the operative report must be available;~8. Prior to surgery there was imaging evidence of measurable progressive disease (PD);~9. Start of radiotherapy, if indicated, must occur at least 2 weeks after surgery and/or biopsy;~10. Estimated survival of at least 3 months;~11. Hgb \> 9 gm; absolute neutrophil count (ANC) \> 1500/μl; platelets \> 100,000; Creatinine \< 1.5 times the upper limit of laboratory normal value; Bilirubin \< 2 times the upper limit of laboratory normal value; serum glutamate pyruvate transaminase (SGPT) or serum glutamate oxaloacetate transaminase (SGOT) \< 3 times the upper limit of laboratory normal value;~12. If indicated radiation therapy and chemotherapy must start within 8 weeks of tumor resection or biopsy.~13. Bevacizumab (Avastin) is allowed. If indicated it should be initiated at least 4 weeks post craniotomy or biopsy if the wound has healed well without any drainage or cellulitis;~14. The use of herbal preparation or tetrahydrocannabinol/cannabidiol is strongly discouraged, but not contraindicated;~Exclusion Criteria:~1. Subjects with newly diagnosed GBM~2. Pregnant women or nursing mothers cannot participate in the study. Women of childbearing age must have a negative pregnancy test within 72 hours prior to study entry. Women of childbearing potential must practice medically approved contraceptive precautions;~3. Abnormal hematological results at inclusion with: Neutrophils \< 1,500/mm3; Blood-platelets \< 100,000/mm3~4. Severe or chronic renal insufficiency (creatinine clearance ≤ 30 ml/min);~5. Patient unable to follow procedures, visits, examinations described in the study;~6. Any usual formal indication against imaging examinations (important claustrophobia, pacemaker);~7. History of another malignancy in the previous 2 years, with a disease-free interval of \< 2 years. Patients with prior history of in situ cancer or basal or squamous cell skin cancer, any time prior to screening, are eligible;~8. OPTUNE device is not permitted in the study;~9. Patients cannot participate to any clinical trials utilizing a liquid biomarker or imaging studies that impact the overall survival.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Physician Choice treatment (Type: ACTIVE_COMPARATOR): Participants will be treated with control chemotherapy treatment (standard-of-care chemotherapy chosen by the Physician from the provided list).~Control chemotherapy treatment will be chosen from any of the following standard-of-care chemotherapy drugs or combinations:~* Carboplatin;~* Irinotecan;~* Etoposide;~* BCNU;~* CCNU;~* Temozolomide;~* Procarbazine;~* Vincristine;~* Imatinib;~* Procarbazine, CCNU, Vincristine;~* Carboplatin, Irinotecan;~* Carboplatin, Etoposide;~* Temozolomide, Etoposide;~* Temozolomide, Imatinib. The treating physician will NOT receive the ChemoID assay results from the ChemoID lab.
- ChemoID-guided treatment (Type: EXPERIMENTAL): Participants will be treated with ChemoID-guided standard-of-care chemotherapy drugs from the provided list.~ChemoID-guided treatment will be chosen from the following standard-of-care chemotherapy drugs or combinations:~* Carboplatin;~* Irinotecan;~* Etoposide;~* BCNU;~* CCNU;~* Temozolomide;~* Procarbazine;~* Vincristine;~* Imatinib;~* Procarbazine, CCNU, Vincristine;~* Carboplatin, Irinotecan;~* Carboplatin, Etoposide;~* Temozolomide, Etoposide;~* Temozolomide, Imatinib.~The treating physician will receive the ChemoID assay results from the ChemoID lab.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete